——————————————————————————– Corporate News übermittelt durch euro adhoc. Für den Inhalt ist der Emittent/Meldungsgeber verantwortlich. ——————————————————————————– Unternehmen/Forschung/Entwicklung/Molekulardiagnostik Berlin, Deutschland, und Seattle, WA, USA, 5. Januar 2012 (euro adhoc) – Das Deutsch-Amerikanische Krebsdiagnostik-Unternehmen Epigenomics AG (Frankfurt Prime Standard: ECX) freut sich die Veröffentlichung einer unter der Leitung von Prof. Matthias Ebert durchgeführten Studie mit dem Titel “TFAP2E-DKK4 [...]
Tag Archive > Colorectal
EANS-Adhoc: Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG Completes U.S. Clinical Validation Study for Colorectal Cancer Blood Test Epi proColon; Provides Update on U.S. Regulatory Plans
——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– New Products/molecular diagnostics 09.12.2011 Berlin, Germany, December 9, 2011 – Epigenomics AG (ISIN: DE000A1K0516) reports the completion of the clinical validation study [...]
EANS-News: Epigenomics AG Completes U.S. Clinical Validation Study for Colorectal Cancer Blood Test Epi proColon; Provides Update on U.S. Regulatory Plans
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/New Products/molecular diagnostics Subtitle: Conference Call Scheduled for today, 9thDecember 2011 at 4 pm CET Berlin, Germany, and Seattle, WA, U.S.A., December 9, 2011 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer [...]
EANS-News: Epigenomics announces the European launch of Epi proColon® 2.0 CE
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– New Products/Company Information/molecular diagnostics Subtitle: Presentation of the powerful second generation blood test for colorectal cancer screening during UEGW in Stockholm Berlin, Germany, and Stockholm, Sweden, October 25, 2011 (euro adhoc) – Epigenomics AG (Frankfurt Prime [...]
EANS-News: Epigenomics AG reports EpiproColon® 2.0 finds 95% of cancers in clinical study
——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/New Products/molecular diagnostics Subtitle: Study provides clinical evidence for CE-marking in Europe and paves way to US pivotal clinical trial for submission to FDA before year-end Berlin, Germany, and Seattle, WA, USA, September 19, 2011 [...]
EANS-Adhoc: Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG Announces Restructuring of U.S. and European Operations
——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Company Information/molecular diagnostic 10.08.2011 Berlin, Germany, and Seattle, WA, U.S.A., August 10, 2011 – Epigenomics AG (ISIN: DE000A1K0516) today released plans to [...]
Colorectal Cancer Patients Call for European Action / The Power of Patient Voice: Europe’s largest patient conference to fight the killer disease has been successfully launched
London (ots) – Colorectal cancer (CRC) patients from across Europe benefited greatly from the Colorectal Cancer Patient Conference that took place in Barcelona last weekend: With almost 200 attendees from 27 countries the first pan-European conference of its kind united CRC patients and experts from the whole continent to share the latest knowledge about prevention, [...]
Brennpunkt Darmkrebs: Europas Patienten rufen zu verstärktem Handeln auf / Europas erste Patientenkonferenz zur Bekämpfung der tödlichen Krankheit erfreute sich größter Resonanz
London (ots) – Darmkrebspatienten aus ganz Europa werden noch lange von der Patientenkonferenz “Colorectal Cancer Patient Conference”, die am Wochenende in Barcelona stattfand, profitieren: Mit knapp 200 Teilnehmern aus 27 Ländern vereinte die erste Konferenz ihrer Art Darmkrebspatienten und Experten des gesamten Kontinents, damit sich diese zu Prävention, Diagnose von und Therapiemöglichkeiten bei Darmkrebs austauschen. [...]
The Power of Patient Voice: Ein vereinigtes Europa gegen Darmkrebs / Erste europäische Patientenkonferenz soll Bürger für den Kampf gegen die tödliche Krankheit mobilisieren
London/Barcelona (ots) – Die europäische Darmkrebspatientenkonferenz “Colorectal Cancer Patient Conference” (CCPC) ist die erste gemeinsame, interdisziplinäre Veranstaltung ihrer Art und wird von Krebsexperten sowie anderen relevanten Meinungsführern aus ganz Europa und den USA getragen. Die am schnellsten wachsende europäische Initiative für Darmkrebspatienten europacolon lädt Patienten, Angehörige, Selbsthilfegruppen, Pflegekräfte und Medizinexperten des ganzen Kontinents zu dieser [...]
Agendia Announces Colorectal Cancer Collaboration With AstraZeneca and The Netherlands Cancer Institute
Amsterdam and Irvine, California (ots/PRNewswire) – Agendia, an innovative molecular cancer diagnostics company, today announced that it has partnered with AstraZeneca and The Netherlands Cancer Institute (NKI) to accelerate the development of targeted therapies for colorectal cancer patients. The announcement marks a unique collaboration between Agendia, developer of the “MammaPrint” breast cancer molecular diagnostic test, [...]
Amgen to Appeal CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
Thousand Oaks, California (ots/PRNewswire) – Amgen announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic [...]
Amgen Statement on CHMP Opinion on Vectibix(R) (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer
Thousand Oaks, California (ots/PRNewswire) – Amgen today issued the following statement: Amgen has received notice that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for Amgen’s application to extend the marketing authorization in Europe for Vectibix(R) (panitumumab) to include combination with chemotherapy for [...]
EANS-Adhoc: Ad hoc Announcement According to §15 WpHG (German Securities Trading Act): Epigenomics AG signs Collaboration Agreement in Colorectal Cancer Blood Testing with QIAGEN N.V.
——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– New Products/Molecular diagnostics 28.02.2011 Berlin, Germany, February 28, 2011 – Epigenomics AG (ISIN: DE000A0BVT96) today signed an option agreement in colorectal cancer [...]
EANS-News: Epigenomics and QIAGEN Sign Collaboration Agreement in Colorectal Cancer Blood Testing
QIAGEN acquires options to mSEPT9 biomarker and DNA methylation technologies; QIAGEN granted license to pursue Septin9 product related R&D ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Joint Ventures/Cooperation/Collaboration/New Products/Molecular diagnostics Subtitle: QIAGEN acquires options to mSEPT9 biomarker and DNA methylation technologies; QIAGEN granted [...]
Kanadisches Mitglied von "Bowel Cancer International" steigert Krebsbewusstsein durch seinen "International Public Service Announcement Contest"
Toronto (ots/PRNewswire) – Die “Colorectal Cancer Association of Canada” (CCAC, kanadische Vereinigung für Kolorektalkrebs) lädt aufstrebende Werbedesigner und Filmemacher ein, ihre Talente einzusetzen, um durch ihre Teilnahme an dem zweiten Jahreswettbewerb “International Public Service Announcement (PSA) Contest” (Ausschreibungswettbewerb für öffentliche Institutionen) weltweit das Bewusstsein für Kolorektalkrebs zu fördern. Neben Bargeldpreisen von bis zu $4.500,- CAD [...]
